{'fraction_non_alphanumeric': 0.023479188900747065, 'fraction_numerical': 0.012806830309498399, 'mean_word_length': 5.051612903225807, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 1, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Association of vitamin D pathway SNPs and clinical response to interferon in a cohort of HBeAg-negative patients.

AIM
Vitamin D modulates biological processes; an influence of vitamin D levels and genetic variants was identified concerning hepatitis B virus infection. We evaluated the role of some SNPs of vitamin D pathway genes in some clinical features of hepatitis B affected patients treated with pegylated interferon.


METHODS
We investigated SNPs in IL-28B, CYP27B1, CYP27A1, CYP24A1, VDBP and VDR genes, through real-time PCR.


RESULTS
 VDRApaI SNP was associated to viral load and HBsAg presence at different timings. In logistic regression analyses, VDRApaI AA genotype predicted baseline viral load >6 Log IU/ml (marker of nonresponse), and both virological and biochemical responses.


CONCLUSION
Pharmacogenetic data could help physicians in the prediction of patients with higher probability to achieve a good response.